Appointments

Canaud is a leading authority on kidney disease and dialysis, with over 40 years in the field and more than 350 peer-reviewed articles on the subject. He is currently Emeritus Professor of Nephrology at the Montpellier University School of Medicine, France and has previously headed the Nephrology, Dialysis and Intensive Care Department at Lapeyronie University Hospital in Montpellier, France.

Richard Boyd, Invisius’ chief executive officer, commented: “We are delighted and honored to have Professor Canaud join Invizius at an important time of growth and development for the company. We are now beginning the first-in-human study of H-Guard following recent approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Professor

Canaud’s unrivalled experience in the field of nephrology will be instrumental as we look to transform the treatment landscape for dialysis patients.”

Canaud added: “Invizius’ unique product H-Guard has the potential to reduce the therapeutic burden and save patients’ lives by addressing the inappropriate activation of the complement system. In spite of significant advances in the field of biocompatibility, studies have demonstrated that the persistent activation of the complement system by extracorporeal blood purification or nanomedicine therapy remains potentially harmful in the long and short term for patients exposed to these therapies. By targeting factor H and inhibiting both the alternate complement activation pathway and its amplification loop with H-Guard, we have the ability and potential to make a tremendous difference to patients while mitigating associated risks.”